Back to results
US 2016/0102075 A1Published application
Unsaturated nitrogen heterocyclic compounds useful as pde10 inhibitors
AssigneeAmgen Inc.
InventorsJennifer R. ALLEN, Jian J. CHEN, Michael J. FROHN, Essa Hu HARRINGTON, Qingyian LIU, Alexander J. PICKRELL, Shannon RUMFELT, Robert M. RZASA, Wenge ZHONG
Life of this patent
Estimating the term…
Abstract
Unsaturated nitrogen heterocyclic compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
Claims59
A compound of formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- X1 is N or CR6;
- X2 is N or CR2;
- X3 is N or CR3;
- X4 is N or CR6;
- X5 is N or CR6;
- wherein 1 to 2 of X1, X2, X3, X4 and X5 are N;
- R1 is halo, C1-8alk, C1-4haloalk, —ORc, —N(Ra)C(═O)Rb, —C(═O)Ra, —C(═O)Rc, —C(═O)—O—Ra, —NRaRc, —N(Rc)C(═O)Rb, —N(Ra)C(═O)Rc, —C(═O)NRaRb, —C(═O)NRaRc, or C0-4alk-L1;
- wherein said C1-8alk group is substituted by 0, 1, 2 or 3 groups which are halo, C1-3haloalk, —OH, —OC1-4alk, —NH2, —NHC1-4alk, —OC(═O)C1-4alk, or —N(C1-4alk)C1-4alk;
- Y is a C0-4alk, —C(═O), SO, or SO2;
- each R2 and R3 is independently R1, H, halo, CN, OH, —OC1-4alk, C1-4alk, C1-4haloalk, —C1-6alkORa, —C(═O)C1-4alk, —C(═O)NRaRa, —C0-4alkNH—C(═O)Ra, or Rc;
- or alternatively the ring containing X1, X2, X3, X4 and X5 can be fused to ring A, ring B, or ring C;
- each having the formula:
- wherein each said ring A, ring B, or ring C is a fused 4- to 6-membered-saturated, -partially saturated, or -unsaturated-carbocyclic or -heterocyclic ring containing 0, 1, 2, or 3 heteroatoms;
- and is substituted by 0, 1, or 2 R10 groups;
- R4a is H, OH, halo, C1-4alk, or C1-4haloalk;
- R4b is halo, CN, OH, OC1-4alk, C1-4alk, C1-4haloalk, or oxo;
- R5 is —C1-6alkORa, 5- to 6-membered heteroaryl, unsaturated 9- to 10-membered bicyclo-heterocyclic ring, or 11- to 15-membered tricyclo-heterocyclic ring;
- R5 ring is substituted by 0, 1, 2, 3, or 4 R8 groups;
- R6 is independently R1, H, halo, CN, OH, OC1-4alk, C1-4alk or C1-4haloalk;
- m is 0, 1, 2, 3, or 4;
- each of p and q is independently 0, 1, 2, 3, 4, 5, or 6;
- wherein the sum of p and q is 2 to 6;
- the ring containing p and q contains 0, 1, or 2 double bonds;
- Ra is independently H or Rb;
- Rb is independently phenyl, benzyl, or C1-6alk, wherein said phenyl, benzyl, and C1-6alk are substituted by 0, 1, 2 or 3 substituents which are, independently, halo, C1-4alk, C1-3haloalk, —OH, —OC1-4alk, —NH2, —NHC1-4alk, —OC(═O)C1-4alk, or —N(C1-4alk)C1-4alk;
- Rc is C0-4alk-L2;
- each L1 is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms which are O or S;
- L1 is independently substituted by 0, 1, 2 or 3 R9 groups;
- each L2 is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms which are O or S;
- L2 is independently substituted by 0, 1, 2 or 3 R11 groups;
- R8 is halo, CN, OH, OC1-4alk, C1-4alk, C1-4haloalk, OC1-4haloalk, —C(═O)Rb, —C(═O)Rc, —C(═O)NHRb, —C(═O)NHRc, —S(═O)2Rb, —S(═O)2Rc, —S(═O)2NRaRa, Rb, Rc, NO2, ORb, or ORc;
- R9 is halo, C1-6alk, C1-4haloalk, —ORa, —OC1-4haloalk, CN, —C(═O)Rb, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —OC(═O)Rb, —OC(═O)NRaRa, —OC1-6alkNRaRa, —OC1-6alkORa, —SRa, —S(═O)Rb, —S(═O)2Rb, —S(═O)2NRaRa, —NRaRa, —N(Ra)C(═O)Rb, —N(Ra)C(═O)ORb, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Rb, —N(Ra)S(═O)2NRaRa, —NRaC1-6alkNRaRa, —NRaC1-6alkORa, —C1-6alkNRaRa, —C1-6alkORa, —C1-6alkN(Ra)C(═O)Rb, —C1-6alkOC(═O)Rb, —C1-6alkC(═O)NRaRa, —C1-6alkC(═O)ORa, oxo, or Rc;
- R10 is oxo, C1-6alk, C1-3haloalk, —OH, —OC1-4alk, —NH2, —NHC1-4alk, —OC(═O)C1-4alk, or —N(C1-4alk)C1-4alk;
- and
- R11 is halo, C1-6alk, C1-4haloalk, —ORa, —OC1-4haloalk, CN, —C(═O)Rb, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —OC(═O)Rb, —OC(═O)NRaRa, —OC1-6alkNRaRa, —OC1-6alkORa, —SRa, —S(═O)Rb, —S(═O)2Rb, —S(═O)2NRaRa, —NRaRa, —N(Ra)C(═O)Rb, —N(Ra)C(═O)ORb, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Rb, —N(Ra)S(═O)2NRaRa, —NRaC1-6alkNRaRa, —NRaC1-6alkORa, —C1-6alkNRaRa, —C1-6alkORa, —C1-6alkN(Ra)C(═O)Rb, —C1-6alkOC(═O)Rb, —C1-6alkC(═O)NRaRa, —C1-6alkC(═O)ORa, or oxo.
33 more elements
A compound of formula II:
- or a pharmaceutically acceptable salt thereof, wherein:
- Ring D is -L1;
- X1 is N or CR6;
- X2 is N or CR2;
- X3 is N or CR3;
- X4 is N or CR6;
- wherein 1 to 2 of X1, X2, X3, and X4 are N;
- Y is a C0-4alk, —C(═O), SO, or SO2;
- each R2 and R3 is independently H, halo, CN, OH, —OC1-4alk, C1-4alk, C1-4haloalk, —C1-6alkORa, —C(═O)C1-4alk, —C(═O)NRaRa, —C0-4alkNH—C(═O)Ra, or Rc;
- or alternatively the ring containing X1, X2, X3, X4 and X5 can be fused to ring A, ring B, or ring C;
- having the formula:
- wherein each said ring A, ring B, or ring C is a fused 4- to 6-membered-saturated, -partially saturated, or -unsaturated-carbocyclic or -heterocyclic ring containing 0, 1, 2, or 3 heteroatoms;
- and is substituted by 0, 1, or 2 R10 groups;
- R4a is H, OH, halo, C1-4alk, or C1-4haloalk;
- R4b is halo, CN, OH, OC1-4alk, C1-4alk, C1-4haloalk, or oxo;
- R5 is pyridinyl or unsaturated 9- to 10-membered bicyclo-heterocyclic ring;
- wherein each R5 is substituted by 0, 1, 2 or 3 R8 groups;
- R6 is independently H, halo, CN, OH, OC1-4alk, C1-4alk or C1-4haloalk;
- m is 0, 1, 2, 3, or 4;
- each of p and q is independently 0, 1, 2, 3, 4, 5, or 6;
- wherein the sum of p and q is 2 to 6;
- the ring containing p and q contains 0, 1, or 2 double bonds;
- Ra is independently H or Rb;
- Rb is independently phenyl, benzyl, or C1-6alk, wherein said phenyl, benzyl, or C1-6alk substituted by 0, 1, 2 or 3 substituents which are, independently, halo, C1-4alk, C1-3haloalk, —OH, —OC1-4alk, —NH2, —NHC1-4alk, —OC(═O)C1-4alk, or —N(C1-4alk)C1-4alk;
- Rc is C0-4alk-L2;
- each L1 is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms which are O or S;
- wherein each L1 is independently substituted by 0, 1, 2 or 3 R9 groups;
- each L2 is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms which are O or S;
- wherein each L2 is independently substituted by 0, 1, 2 or 3 R11 groups;
- R8 is halo, CN, OH, OC1-4alk, C1-4alk, C1-4haloalk, OC1-4haloalk, —C(═O)Rb, —C(═O)Rc, —C(═O)NHRb, —C(═O)NHRc, —S(═O)2Rb, —S(═O)2Rc, —S(═O)2NRaRa, Rb, Rc, NO2, ORb, or ORc;
- R9 is F, Cl, Br, C1-6alk, C1-4haloalk, —ORa, —OC1-4haloalk, CN, —C(═O)Rb, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —OC(═O)Rb, —OC(═O)NRaRa, —OC1-6alkNRaRa, —OC1-6alkORa, —SRa, —S(═O)Rb, —S(═O)2Rb, —S(═O)2NRaRa, —NRaRa, —N(Ra)C(═O)Rb, —N(Ra)C(═O)ORb, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Rb, —N(Ra)S(═O)2NRaRa, —NRaC1-6alkNRaRa, —NRaC1-6alkORa, —C1-6alkNRaRa, —C1-6alkORa, —C1-6alkN(Ra)C(═O)Rb, —C1-6alkOC(═O)Rb, —C1-6alkC(═O)NRaRa, —C1-6alkC(═O)ORa, oxo, or Rc;
- R10 is oxo, C1-6alk, C1-3haloalk, —OH, —OC1-4alk, —NH2, —NHC1-4alk, —OC(═O)C1-4alk, or —N(C1-4alk)C1-4alk;
- and
- R11 is F, Cl, Br, C1-6alk, C1-4haloalk, —ORa, —OC1-4haloalk, CN, —C(═O)Rb, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —OC(═O)Rb, —OC(═O)NRaRa, —OC1-6alkNRaRa, —OC1-6alkORa, —SRa, —S(═O)Rb, —S(═O)2Rb, —S(═O)2NRaRa, —NRaRa, —N(Ra)C(═O)Rb, —N(Ra)C(═O)ORb, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Rb, —N(Ra)S(═O)2NRaRa, —NRaC1-6alkNRaRa, —NRaC1-6alkORa, —C1-6alkNRaRa, —C1-6alkORa, —C1-6alkN(Ra)C(═O)Rb, —C1-6alkOC(═O)Rb, —C1-6alkC(═O)NRaRa, —C1-6alkC(═O)ORa, or oxo.
31 more elements
Dependencies are inferred from the claim text.